{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+%28Viibryd%29", "query": { "intervention": "Treatment (Viibryd)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+%28Viibryd%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T23:54:35.630Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01838876", "title": "Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Cariprazine", "type": "DRUG" }, { "name": "Antidepressant Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 442, "start_date": "2013-04-29", "completion_date": "2015-07-27", "has_results": true, "last_update_posted_date": "2019-08-21", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 88, "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01838876" }, { "nct_id": "NCT01712321", "title": "Study of Vilazodone to Treat Social Anxiety Disorder", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Social Anxiety Disorder" ], "interventions": [ { "name": "Vilazodone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Medical Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2012-10", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-01-20", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712321" }, { "nct_id": "NCT01844115", "title": "Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Vilazodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 415, "start_date": "2013-04-30", "completion_date": "2014-03-31", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01844115" }, { "nct_id": "NCT02097147", "title": "Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Vilazodone 20 mg", "type": "DRUG" }, { "name": "Vilazodone 40 mg", "type": "DRUG" }, { "name": "Paroxetine 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 202, "start_date": "2014-03", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2015-02-12", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 4, "location_summary": "Miami, Florida • Overland Park, Kansas • Saint Paul, Minnesota + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02097147" }, { "nct_id": "NCT01608295", "title": "Vilazodone for Treatment of Geriatric Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Vilazodone; Viibryd", "type": "DRUG" }, { "name": "Paroxetine; Paxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 65, "start_date": "2012-07", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2018-05-11", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01608295" }, { "nct_id": "NCT01766401", "title": "Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Vilazadone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 402, "start_date": "2013-01-31", "completion_date": "2014-01-29", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 30, "location_summary": "Arcadia, California • Beverly Hills, California • Encino, California + 26 more", "locations": [ { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Redlands", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01766401" }, { "nct_id": "NCT00285376", "title": "Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Depressive Disorder, Major" ], "interventions": [ { "name": "vilazodone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genaissance Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 410, "start_date": "2006-02", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2008-02-21", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 15, "location_summary": "Los Alamitos, California • Newport Beach, California • Northridge, California + 12 more", "locations": [ { "city": "Los Alamitos", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00285376" }, { "nct_id": "NCT01999920", "title": "Vilazodone for Separation Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Separation Anxiety Disorder" ], "interventions": [ { "name": "Vilazodone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 24, "start_date": "2013-12", "completion_date": "2017-12-30", "has_results": true, "last_update_posted_date": "2018-03-07", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01999920" }, { "nct_id": "NCT02893371", "title": "Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bipolar Disorder" ], "interventions": [ { "name": "Lithium Carbonate", "type": "DRUG" }, { "name": "Lamotrigine", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" }, { "name": "Oxcarbazepine", "type": "DRUG" }, { "name": "Carbamazepine", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Quetiapine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Fluoxetine / Olanzapine", "type": "DRUG" }, { "name": "Haloperidol", "type": "DRUG" }, { "name": "Perphenazine", "type": "DRUG" }, { "name": "Clozapine", "type": "DRUG" }, { "name": "Asenapine", "type": "DRUG" }, { "name": "Lurasidone", "type": "DRUG" }, { "name": "Paliperidone", "type": "DRUG" }, { "name": "Mirtazapine", "type": "DRUG" }, { "name": "Bupropion", "type": "DRUG" }, { "name": "Desvenlafaxine", "type": "DRUG" }, { "name": "Duloxetine", "type": "DRUG" }, { "name": "Venlafaxine", "type": "DRUG" }, { "name": "Citalopram", "type": "DRUG" }, { "name": "Escitalopram", "type": "DRUG" }, { "name": "Fluoxetine", "type": "DRUG" }, { "name": "Fluvoxamine", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" }, { "name": "Sertraline", "type": "DRUG" }, { "name": "Vilazodone", "type": "DRUG" }, { "name": "Doxepin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1037352, "start_date": "2016-09", "completion_date": "2019-06-30", "has_results": false, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893371" }, { "nct_id": "NCT01916824", "title": "Effects of Treatment on Decision-making in Major Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder", "Healthy Controls" ], "interventions": [ { "name": "Any FDA Approved Antidepressant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 53, "start_date": "2013-08", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-11-21", "last_synced_at": "2026-09-20T23:54:35.630Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01916824" } ] }